Doximity, Inc. (DOCS) News
Latest headlines that mention DOCS, newest first · each headline opens the original publisher
- Last price
- $31.45
- Day change
- +1.55%
- Next earnings
- 2026-11-05 AMC
DOCS headlines
latest coverageThis sale was executed under a pre-established Rule 10b5-1 trading plan adopted in February.
Sitaram's sale was driven by tax obligations from option exercises and RSU vesting, not a shift in conviction.
Restricted stock unit vesting triggered a routine sell-to-cover sale, reducing Zatz's direct holdings by 8% while leaving him with $1.3 million in remaining equity.
This non-discretionary sale tied to restricted stock unit vesting reduced the CFO's direct holdings by 3%, though he retains a $12.1 million equity stake in the healthcare platform operator.
Tangney executed a non-discretionary sale to cover tax withholding on vesting equity awards.
Revenue grew 7% as AI adoption accelerated, with AI Scribe users surging 10-fold in July.
GitLab, UiPath, and Asana have similar setups that could lead to big post-earnings jumps.
The leading digital platform for U.S. medical professionals is becoming a formidable force in the AI race.
While one analyst thinks Doximity has a compelling AI opportunity, another worries that the company could cannibalize its core business of medical networking.
Curious about Doximity's potential in the evolving healthcare tech landscape? Tune in as our experts rate its business strength and future growth prospects!
Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale?
Doximity stock has gotten clobbered this year, down 56%. Here's the short thesis for why I think the market's reaction is overdone.
DOCS news alerts
Get an alert by email or push when a new headline mentions DOCS.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.